CD19 and neoplasm: We then compared CD4 and CD8 T cells co-expressing either CD25 or PD-1, NK cells (CD3−/DX5+), NKT cells (CD3+/DX5+), and B cells (CD19 cells) in the different tumor groups (Fig. 5B).